n,n-dimethylarginine has been researched along with Hypertrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arning, E; Baumbach, GL; Bottiglieri, T; Cooke, JP; Dayoub, H; Faraci, FM; Kimoto, M; Lentz, SR; Lynch, CM; Murry, DJ; Rodionov, RN; Stevens, JW; Wilson, KM | 1 |
| Fukami, K; Ishibashi, Y; Maeda, S; Matsui, T; Nishino, Y; Ojima, A; Takeuchi, M; Yamagishi, S | 1 |
2 other study(ies) available for n,n-dimethylarginine and Hypertrophy
| Article | Year |
|---|---|
Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia.
Topics: Acetylcholine; Amidohydrolases; Animals; Arginine; Arterioles; Carotid Artery Thrombosis; Cerebral Arterial Diseases; Diet; Folic Acid Deficiency; Humans; Hyperhomocysteinemia; Hypertrophy; Methionine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Papaverine; Vasodilation; Vasodilator Agents | 2010 |
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Topics: Animals; Arginine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Evaluation, Preclinical; Exenatide; Gene Expression Regulation, Enzymologic; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycation End Products, Advanced; Humans; Hypertrophy; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Kidney Tubules; Macrophages; Male; Peptides; Protein-Arginine N-Methyltransferases; Rats; Rats, Wistar; Reactive Oxygen Species; Receptor for Advanced Glycation End Products; Receptors, Glucagon; Receptors, Immunologic; Repressor Proteins; RNA, Messenger; Venoms | 2013 |